Spotlight On: Lantus® / Lantus® SoloSTAR® (Insulin Glargine Recombinant) / Basaglar® (Insulin Glargine) / Semglee® (Insulin Glargine) / Rezvoglar™ (Insulin Glargine-Aglr) - March 2026

Why It Matters

Accurate claim counting shapes settlement, licensing and market entry strategies in the high‑value diabetes therapeutics sector, influencing competitive dynamics and pricing.

Key Takeaways

• Claims appear in multiple IPRs and lawsuits, counted separately
• Litigation counts each claim once per case, regardless of repetitions
• IPR counts each claim once per proceeding, even under §§102/103
• Infringed claims sourced from complaints or PTAB determinations
• Accurate metrics steer biosimilar licensing and settlement decisions

Pulse Analysis

Insulin glargine remains a cornerstone of diabetes management, generating billions in annual sales worldwide. The therapeutic class’s profitability has attracted a dense web of patents covering formulation, delivery devices, and manufacturing processes. As biosimilar manufacturers prepare to enter the market, the legal landscape becomes a critical barrier or catalyst, depending on how patent claims are enforced. Understanding the underlying patent architecture is essential for investors and industry analysts tracking future revenue streams and competitive pressures.

The Venable report clarifies a nuanced counting methodology that separates litigation from Inter‑Partes Review (IPR) proceedings. In court, a claim is tallied once per case, even if the complaint cites it multiple times, while the PTAB counts each claim once per IPR regardless of whether it is challenged under anticipation (§102) or obviousness (§103). This distinction prevents double‑counting and yields a more precise picture of the total claim exposure facing each insulin glargine product. Such granularity is vital for assessing the true risk of infringement judgments and for forecasting potential royalty obligations.

For stakeholders, the practical upshot is strategic clarity. Patent owners can gauge the breadth of their enforcement portfolio, while biosimilar developers can prioritize which claims to contest, license, or design around. Accurate claim metrics also inform settlement negotiations, allowing parties to quantify exposure and negotiate fair compensation. As the PTAB continues to streamline IPR processes, the ability to interpret claim counts will become an increasingly valuable competency for legal teams and corporate strategists alike.